October 22, 2018 11:25 AM EDT

In key endorsement, Deerfield reserves $65M for drug venture with UNC-Chapel Hill

Amber Tong

Last October, Deerfield Management teamed up with the Broad Institute of MIT and Harvard for a novel approach to pursuing translational research. Just over …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

In key endorsement, Deerfield reserves $65M for drug venture with UNC-Chapel Hill

Amber Tong

Sign up to read this article for free.

WuXi AppTec will sell cell and gene therapy business to private equity firm

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

CMS explains what went into its first round of drug price negotiations

CagriSema’s weight loss data disappointed. What does Novo do next?

FDA approves Lilly's Zepbound for sleep apnea, likely cracking open Medicare market

Exclusive: Florida cancer biotech raises $100M Series A

In key en­dorse­ment, Deer­field re­serves $65M for drug ven­ture with UNC-Chapel Hill

Amber Tong

Sign up to read this article for free.

more like this

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

In key endorsement, Deerfield reserves $65M for drug venture with UNC-Chapel Hill

WuXi AppTec will sell cell and gene therapy business to private equity firm

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

CMS explains what went into its first round of drug price negotiations

CagriSema’s weight loss data disappointed. What does Novo do next?

FDA approves Lilly's Zepbound for sleep apnea, likely cracking open Medicare market

Exclusive: Florida cancer biotech raises $100M Series A